세계의 세포막 투과 펩티드 시장 규모, 점유율 및 동향 분석 보고서 : 최종 용도, 용도, 유형 및 지역별 전망 및 예측(2023-2030년)
Global Cell Penetrating Peptide Market Size, Share & Trends Analysis Report By End-use, By Application (Drug Delivery, Gene Delivery, Diagnostics, Molecular Imaging, and Others), By Type, By Regional Outlook and Forecast, 2023 - 2030
상품코드:1410278
리서치사:KBV Research
발행일:2024년 01월
페이지 정보:영문 239 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세포막 투과 펩티드 시장 규모는 2030년까지 27억 달러에 달할 것으로 예상되며, 예측 기간 동안 10.5%의 CAGR을 나타낼 것으로 예상됩니다.
그러나 CPP는 세포내 세포내 흡수, 직접 이동, 기타 경로 등 다양한 세포내 흡수 메커니즘을 이용하고 있습니다. 메커니즘의 다양성은 CPP의 세포 내 흡수를 연구하는 데 있어 복잡성을 증가시킵니다. 다른 CPP는 물리화학적 특성, 세포 유형 및 기타 요인에 따라 서로 다른 경로를 사용할 수 있습니다. 이러한 다양성을 이해하는 것은 CPP를 특정 치료 용도에 맞게 조정하는 데 매우 중요합니다. 세포가 세포외 물질을 흡수하는 세포내소체는 CPP 내재화의 주요 경로입니다. 따라서 이러한 측면은 향후 몇 년동안 세포막 투과 펩티드에 대한 수요를 감소시킬 것으로 예상됩니다.
또한, 코로나19는 연구 우선순위와 자금 배분을 크게 재편성하여 코로나19 관련 연구와 치료제에 더 많은 초점을 맞추게 했습니다. 이전에는 CPP 연구를 포함한 다양한 분야에 투입되었던 자원이 팬데믹의 긴급한 요구에 대응하기 위해 전환되었으며, CPP 관련을 포함한 많은 연구 프로젝트는 실험실 작업 중단, 연구시설에 대한 물리적 접근 제한, 연구 노력의 우선 순위 재조정 등으로 인해 지연에 직면했습니다. 지연에 직면했습니다. 따라서 코로나19 사태는 시장에 부정적인 영향을 미쳤습니다.
The Global Cell Penetrating Peptide Market size is expected to reach $2.7 billion by 2030, rising at a market growth of 10.5% CAGR during the forecast period.
CPPs offer selectivity in drug delivery, allowing targeted delivery to specific cells or tissues. This targeted approach is advantageous as it minimizes the exposure of healthy cells to therapeutic agents, reducing off-target effects and potential side effects associated with non-specific drug distribution. Consequently, the Chimeric CPPs segment would generate approximately 7.65% share of the market by 2030. CPPs exhibit versatility in delivering various types of therapeutic cargo. They can transport small molecules, peptides, proteins, and nucleic acids, making them suitable for biomedical applications.
Peptide-based therapeutics have gained prominence as a class of drugs with unique properties. They offer specificity in targeting, which can enhance the precision of treatment, and are often associated with lower toxicity and reduced immunogenicity compared to some traditional drugs. This enhanced bioavailability contributes to the overall efficacy of peptide-based therapeutics. These factors will help in the expansion of the market. Moreover, CPPs are crucial in targeted drug delivery, addressing the need for precision in treating chronic diseases. By facilitating the transport of therapeutic agents across cell membranes, CPPs enhance the targeted delivery of drugs to specific cells or tissues affected by chronic conditions. In cancer therapy, CPPs have shown promise in delivering anticancer drugs directly to cancer cells. Thus, these factors will pose lucrative growth prospects for the market.
However, CPPs utilize various cellular uptake mechanisms, including endocytosis, direct translocation, and other pathways. The diversity of mechanisms adds complexity to studying CPP entry into cells. Different CPPs may employ different pathways based on their physicochemical properties, cell type, and other factors. Understanding this diversity is crucial for tailoring CPPs to specific therapeutic applications. Endocytosis, a process where cells engulf extracellular material, is a major pathway for CPP internalization. Therefore, these aspects will reduce demand for cell penetrating peptides in the upcoming years.
Further, the pandemic prompted a significant realignment of research priorities and funding allocations, with a heightened focus on COVID-19-related research and therapeutics. Resources previously directed toward diverse areas, including CPP research, were redirected to address the urgent needs of the pandemic. Many research projects, including those related to CPPs, faced delays due to disruptions in laboratory work, restrictions on physical access to research facilities, and the reprioritization of research efforts. Therefore, the COVID-19 pandemic adversely affected the market.
By End-Use Analysis
Based on end-use, the market is divided into pharmaceutical & biotechnology companies, contract research organizations (CROs), hospitals & clinics, and others. The pharmaceutical and biotechnology companies segment recorded the maximum revenue share in the market in 2022. The pharmaceutical and biotechnology sectors increasingly focus on developing targeted therapies to enhance treatment precision and reduce side effects. CPPs play a crucial role in this context by enabling the targeted delivery of therapeutic agents to specific cells or tissues. This targeted approach aligns with the growing trend of personalized medicine, where therapies are tailored to individual patient profiles. As a result, the segment will grow rapidly in the coming years.
By Application Analysis
On the basis of application, the market is divided into drug delivery, gene delivery, diagnostics, molecular imaging, and others. In 2022, the gene delivery segment witnessed a substantial revenue share in the market. Gene therapy has advanced considerably, with various diseases being treated at the genetic level. CPPs play an important role in gene therapy by acting as carriers for therapeutic genes. By transferring functional or therapeutic genes into target cells, this technique shows promise for treating genetic diseases, malignancies, and other ailments. These factors will assist in the expansion of the segment.
By Type Analysis
Based on type, the market is segmented into protein derived CPPs, synthetic CPPs, and chimeric CPPs. The synthetic CPPs segment held the largest revenue share in the market in 2022. Synthetic CPPs often exhibit enhanced stability compared to natural CPPs. The synthetic design allows for incorporating modifications that improve resistance to enzymatic degradation and enhance overall stability in physiological conditions. This increased stability contributes to improved bioavailability and sustained therapeutic effects, addressing challenges associated with the rapid degradation of peptides. These factors will boost the demand in the segment.
By Regional Analysis
By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. In 2022, the Europe segment acquired a considerable revenue share in the market. Europe has witnessed increased investments in biotechnology, which includes areas such as drug development and delivery technologies. The cell-penetrating peptide market has likely benefited from these investments, leading to advancements in research and the potential commercialization of CPP-based products. These aspects will fuel the expansion of the segment.
List of Key Companies Profiled
Biosynth Ltd
Creative Peptides
Cupid Peptide Company Limited
Alta Bioscience Ltd
AnaSpec Inc. (Kaneka Eurogentec S.A.) (Kaneka Corporation)
Peptomyc SL
PolyPeptide Group AG
Bachem Holding AG (Ingro Finanz AG)
Sarepta Therapeutics, Inc.
Revance Therapeutics, Inc.
Global Cell Penetrating Peptide Market Report Segmentation
By End-use
Pharmaceutical and Biotechnology Companies
Contract Research Organization (CROs)
Hospitals & Clinics
Others
By Application
Drug Delivery
Gene Delivery
Diagnostics
Molecular Imaging
Others
By Type
Synthetic CPPs
Protein-derived CPPs
Chimeric CPPs
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Taiwan
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Cell Penetrating Peptide Market, by End-use
1.4.2 Global Cell Penetrating Peptide Market, by Application
1.4.3 Global Cell Penetrating Peptide Market, by Type
1.4.4 Global Cell Penetrating Peptide Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter's Five Forces Analysis
Chapter 4. Global Cell Penetrating Peptide Market, by End-use
4.1 Global Pharmaceutical and Biotechnology Companies Market, by Region
4.2 Global Contract Research Organization (CROs) Market, by Region
4.3 Global Hospitals & Clinics Market, by Region
4.4 Global Others Market, by Region
Chapter 5. Global Cell Penetrating Peptide Market, by Application
5.1 Global Drug Delivery Market, by Region
5.2 Global Gene Delivery Market, by Region
5.3 Global Diagnostics Market, by Region
5.4 Global Molecular Imaging Market, by Region
5.5 Global Others Market, by Region
Chapter 6. Global Cell Penetrating Peptide Market, by Type
6.1 Global Synthetic CPPs Market, by Region
6.2 Global Protein-derived CPPs Market, by Region
6.3 Global Chimeric CPPs Market, by Region
Chapter 7. Global Cell Penetrating Peptide Market, by Region
7.1 North America Cell Penetrating Peptide Market
7.1.1 North America Cell Penetrating Peptide Market, by End-use
7.1.1.1 North America Pharmaceutical and Biotechnology Companies Market, by Country
7.1.1.2 North America Contract Research Organization (CROs) Market, by Country
7.1.1.3 North America Hospitals & Clinics Market, by Country
7.1.1.4 North America Others Market, by Country
7.1.2 North America Cell Penetrating Peptide Market, by Application
7.1.2.1 North America Drug Delivery Market, by Country
7.1.2.2 North America Gene Delivery Market, by Country
7.1.2.3 North America Diagnostics Market, by Country
7.1.2.4 North America Molecular Imaging Market, by Country
7.1.2.5 North America Others Market, by Country
7.1.3 North America Cell Penetrating Peptide Market, by Type
7.1.3.1 North America Synthetic CPPs Market, by Country
7.1.3.2 North America Protein-derived CPPs Market, by Country
7.1.3.3 North America Chimeric CPPs Market, by Country
7.1.4 North America Cell Penetrating Peptide Market, by Country
7.1.4.1 US Cell Penetrating Peptide Market
7.1.4.1.1 US Cell Penetrating Peptide Market, by End-use
7.1.4.1.2 US Cell Penetrating Peptide Market, by Application
7.1.4.1.3 US Cell Penetrating Peptide Market, by Type
7.1.4.2 Canada Cell Penetrating Peptide Market
7.1.4.2.1 Canada Cell Penetrating Peptide Market, by End-use
7.1.4.2.2 Canada Cell Penetrating Peptide Market, by Application
7.1.4.2.3 Canada Cell Penetrating Peptide Market, by Type
7.1.4.3 Mexico Cell Penetrating Peptide Market
7.1.4.3.1 Mexico Cell Penetrating Peptide Market, by End-use
7.1.4.3.2 Mexico Cell Penetrating Peptide Market, by Application
7.1.4.3.3 Mexico Cell Penetrating Peptide Market, by Type
7.1.4.4 Rest of North America Cell Penetrating Peptide Market
7.1.4.4.1 Rest of North America Cell Penetrating Peptide Market, by End-use
7.1.4.4.2 Rest of North America Cell Penetrating Peptide Market, by Application
7.1.4.4.3 Rest of North America Cell Penetrating Peptide Market, by Type
7.2 Europe Cell Penetrating Peptide Market
7.2.1 Europe Cell Penetrating Peptide Market, by End-use
7.2.1.1 Europe Pharmaceutical and Biotechnology Companies Market, by Country
7.2.1.2 Europe Contract Research Organization (CROs) Market, by Country
7.2.1.3 Europe Hospitals & Clinics Market, by Country
7.2.1.4 Europe Others Market, by Country
7.2.2 Europe Cell Penetrating Peptide Market, by Application
7.2.2.1 Europe Drug Delivery Market, by Country
7.2.2.2 Europe Gene Delivery Market, by Country
7.2.2.3 Europe Diagnostics Market, by Country
7.2.2.4 Europe Molecular Imaging Market, by Country
7.2.2.5 Europe Others Market, by Country
7.2.3 Europe Cell Penetrating Peptide Market, by Type
7.2.3.1 Europe Synthetic CPPs Market, by Country
7.2.3.2 Europe Protein-derived CPPs Market, by Country
7.2.3.3 Europe Chimeric CPPs Market, by Country
7.2.4 Europe Cell Penetrating Peptide Market, by Country
7.2.4.1 Germany Cell Penetrating Peptide Market
7.2.4.1.1 Germany Cell Penetrating Peptide Market, by End-use
7.2.4.1.2 Germany Cell Penetrating Peptide Market, by Application
7.2.4.1.3 Germany Cell Penetrating Peptide Market, by Type
7.2.4.2 UK Cell Penetrating Peptide Market
7.2.4.2.1 UK Cell Penetrating Peptide Market, by End-use
7.2.4.2.2 UK Cell Penetrating Peptide Market, by Application
7.2.4.2.3 UK Cell Penetrating Peptide Market, by Type
7.2.4.3 France Cell Penetrating Peptide Market
7.2.4.3.1 France Cell Penetrating Peptide Market, by End-use
7.2.4.3.2 France Cell Penetrating Peptide Market, by Application
7.2.4.3.3 France Cell Penetrating Peptide Market, by Type
7.2.4.4 Russia Cell Penetrating Peptide Market
7.2.4.4.1 Russia Cell Penetrating Peptide Market, by End-use
7.2.4.4.2 Russia Cell Penetrating Peptide Market, by Application
7.2.4.4.3 Russia Cell Penetrating Peptide Market, by Type
7.2.4.5 Spain Cell Penetrating Peptide Market
7.2.4.5.1 Spain Cell Penetrating Peptide Market, by End-use
7.2.4.5.2 Spain Cell Penetrating Peptide Market, by Application
7.2.4.5.3 Spain Cell Penetrating Peptide Market, by Type
7.2.4.6 Italy Cell Penetrating Peptide Market
7.2.4.6.1 Italy Cell Penetrating Peptide Market, by End-use
7.2.4.6.2 Italy Cell Penetrating Peptide Market, by Application
7.2.4.6.3 Italy Cell Penetrating Peptide Market, by Type
7.2.4.7 Rest of Europe Cell Penetrating Peptide Market
7.2.4.7.1 Rest of Europe Cell Penetrating Peptide Market, by End-use
7.2.4.7.2 Rest of Europe Cell Penetrating Peptide Market, by Application
7.2.4.7.3 Rest of Europe Cell Penetrating Peptide Market, by Type
7.3 Asia Pacific Cell Penetrating Peptide Market
7.3.1 Asia Pacific Cell Penetrating Peptide Market, by End-use
7.3.1.1 Asia Pacific Pharmaceutical and Biotechnology Companies Market, by Country
7.3.1.2 Asia Pacific Contract Research Organization (CROs) Market, by Country
7.3.1.3 Asia Pacific Hospitals & Clinics Market, by Country
7.3.1.4 Asia Pacific Others Market, by Country
7.3.2 Asia Pacific Cell Penetrating Peptide Market, by Application
7.3.2.1 Asia Pacific Drug Delivery Market, by Country
7.3.2.2 Asia Pacific Gene Delivery Market, by Country
7.3.2.3 Asia Pacific Diagnostics Market, by Country
7.3.2.4 Asia Pacific Molecular Imaging Market, by Country
7.3.2.5 Asia Pacific Others Market, by Country
7.3.3 Asia Pacific Cell Penetrating Peptide Market, by Type
7.3.3.1 Asia Pacific Synthetic CPPs Market, by Country
7.3.3.2 Asia Pacific Protein-derived CPPs Market, by Country
7.3.3.3 Asia Pacific Chimeric CPPs Market, by Country
7.3.4 Asia Pacific Cell Penetrating Peptide Market, by Country
7.3.4.1 China Cell Penetrating Peptide Market
7.3.4.1.1 China Cell Penetrating Peptide Market, by End-use
7.3.4.1.2 China Cell Penetrating Peptide Market, by Application
7.3.4.1.3 China Cell Penetrating Peptide Market, by Type
7.3.4.2 Japan Cell Penetrating Peptide Market
7.3.4.2.1 Japan Cell Penetrating Peptide Market, by End-use
7.3.4.2.2 Japan Cell Penetrating Peptide Market, by Application
7.3.4.2.3 Japan Cell Penetrating Peptide Market, by Type
7.3.4.3 India Cell Penetrating Peptide Market
7.3.4.3.1 India Cell Penetrating Peptide Market, by End-use
7.3.4.3.2 India Cell Penetrating Peptide Market, by Application
7.3.4.3.3 India Cell Penetrating Peptide Market, by Type
7.3.4.4 South Korea Cell Penetrating Peptide Market
7.3.4.4.1 South Korea Cell Penetrating Peptide Market, by End-use
7.3.4.4.2 South Korea Cell Penetrating Peptide Market, by Application
7.3.4.4.3 South Korea Cell Penetrating Peptide Market, by Type
7.3.4.5 Taiwan Cell Penetrating Peptide Market
7.3.4.5.1 Taiwan Cell Penetrating Peptide Market, by End-use
7.3.4.5.2 Taiwan Cell Penetrating Peptide Market, by Application
7.3.4.5.3 Taiwan Cell Penetrating Peptide Market, by Type
7.3.4.6 Malaysia Cell Penetrating Peptide Market
7.3.4.6.1 Malaysia Cell Penetrating Peptide Market, by End-use
7.3.4.6.2 Malaysia Cell Penetrating Peptide Market, by Application
7.3.4.6.3 Malaysia Cell Penetrating Peptide Market, by Type
7.3.4.7 Rest of Asia Pacific Cell Penetrating Peptide Market
7.3.4.7.1 Rest of Asia Pacific Cell Penetrating Peptide Market, by End-use
7.3.4.7.2 Rest of Asia Pacific Cell Penetrating Peptide Market, by Application
7.3.4.7.3 Rest of Asia Pacific Cell Penetrating Peptide Market, by Type
7.4 LAMEA Cell Penetrating Peptide Market
7.4.1 LAMEA Cell Penetrating Peptide Market, by End-use
7.4.1.1 LAMEA Pharmaceutical and Biotechnology Companies Market, by Country
7.4.1.2 LAMEA Contract Research Organization (CROs) Market, by Country
7.4.1.3 LAMEA Hospitals & Clinics Market, by Country
7.4.1.4 LAMEA Others Market, by Country
7.4.2 LAMEA Cell Penetrating Peptide Market, by Application
7.4.2.1 LAMEA Drug Delivery Market, by Country
7.4.2.2 LAMEA Gene Delivery Market, by Country
7.4.2.3 LAMEA Diagnostics Market, by Country
7.4.2.4 LAMEA Molecular Imaging Market, by Country
7.4.2.5 LAMEA Others Market, by Country
7.4.3 LAMEA Cell Penetrating Peptide Market, by Type
7.4.3.1 LAMEA Synthetic CPPs Market, by Country
7.4.3.2 LAMEA Protein-derived CPPs Market, by Country
7.4.3.3 LAMEA Chimeric CPPs Market, by Country
7.4.4 LAMEA Cell Penetrating Peptide Market, by Country
7.4.4.1 Brazil Cell Penetrating Peptide Market
7.4.4.1.1 Brazil Cell Penetrating Peptide Market, by End-use
7.4.4.1.2 Brazil Cell Penetrating Peptide Market, by Application
7.4.4.1.3 Brazil Cell Penetrating Peptide Market, by Type
7.4.4.2 Argentina Cell Penetrating Peptide Market
7.4.4.2.1 Argentina Cell Penetrating Peptide Market, by End-use
7.4.4.2.2 Argentina Cell Penetrating Peptide Market, by Application
7.4.4.2.3 Argentina Cell Penetrating Peptide Market, by Type
7.4.4.3 UAE Cell Penetrating Peptide Market
7.4.4.3.1 UAE Cell Penetrating Peptide Market, by End-use
7.4.4.3.2 UAE Cell Penetrating Peptide Market, by Application
7.4.4.3.3 UAE Cell Penetrating Peptide Market, by Type
7.4.4.4 Saudi Arabia Cell Penetrating Peptide Market
7.4.4.4.1 Saudi Arabia Cell Penetrating Peptide Market, by End-use
7.4.4.4.2 Saudi Arabia Cell Penetrating Peptide Market, by Application
7.4.4.4.3 Saudi Arabia Cell Penetrating Peptide Market, by Type
7.4.4.5 South Africa Cell Penetrating Peptide Market
7.4.4.5.1 South Africa Cell Penetrating Peptide Market, by End-use
7.4.4.5.2 South Africa Cell Penetrating Peptide Market, by Application
7.4.4.5.3 South Africa Cell Penetrating Peptide Market, by Type
7.4.4.6 Nigeria Cell Penetrating Peptide Market
7.4.4.6.1 Nigeria Cell Penetrating Peptide Market, by End-use
7.4.4.6.2 Nigeria Cell Penetrating Peptide Market, by Application
7.4.4.6.3 Nigeria Cell Penetrating Peptide Market, by Type
7.4.4.7 Rest of LAMEA Cell Penetrating Peptide Market
7.4.4.7.1 Rest of LAMEA Cell Penetrating Peptide Market, by End-use
7.4.4.7.2 Rest of LAMEA Cell Penetrating Peptide Market, by Application
7.4.4.7.3 Rest of LAMEA Cell Penetrating Peptide Market, by Type
Chapter 8. Company Profiles
8.1 Biosynth Ltd
8.1.1 Company Overview
8.1.2 SWOT Analysis
8.2 Creative Peptides
8.2.1 Company Overview
8.2.2 SWOT Analysis
8.3 Cupid Peptide Company Limited
8.3.1 Company Overview
8.3.2 SWOT Analysis
8.4 Alta Bioscience Ltd
8.4.1 Company Overview
8.4.2 SWOT Analysis
8.5 AnaSpec Inc. (Kaneka Eurogentec S.A.) (Kaneka Corporation)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 Peptomyc SL
8.6.1 Company Overview
8.6.2 SWOT Analysis
8.7 PolyPeptide Group AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 SWOT Analysis
8.8 Bachem Holding AG (Ingro Finanz AG)
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 SWOT Analysis
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.10. Revance Therapeutics, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis
Chapter 9. Winning Imperatives of Cell Penetrating Peptide Market
